Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Second quarter in brief
- In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
- The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate and MRI-data) were achieved and in line with previous studies
- Out-licensing activities are continuing for tasquinimod, paquinimod and SILC
Events after the end of the period
- Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company July 1, 2017
- In July, a patent application for the use of ANYARA in combination with PD-1 inhibitors for the treatment of cancer was published on WIPO's (World Intellectual Property Organization) website www.wipo.int
Financial summary
| SEK M | April-June | Jan.-June | Full-year | |||||
| 2017 | 2016 | 2017 | 2016 | 2016 | ||||
| Net sales | 5.1 | 3.9 | 9.8 | 7.9 | 19.0 | |||
| Operating loss | -23.1 | -14.5 | -37.7 | -30.6 | -55.1 | |||
| Loss for the period | -24.4 | -15.5 | -40.2 | -32.3 | -59.6 | |||
| Loss per share, before and after dilution (SEK) | -0.25 | -0.17 | -0.42 | -0.36 | -0.65 | |||
| Cash and cash equivalents (at the end of the period) | 47.7 | 57.4 | 77.7 | |||||
For further information, please contact:
| Helén Tuvesson, President & CEO Tel: +46 (0)46-19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: 046 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0c8b53eb-d197-4c8b-bd63-aa1de2d640d2
